← Leaderboards
Sara Elizabeth Maloney
Colorado State University
$2,164,235
Attributed
$6,492,704
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$6,492,704 · 3
By mechanism
R01$6,492,704 · 3
Top collaborators
- Mercedes Gonzalez-Juarrero5 shared
- Bernd Meibohm5 shared
- Gauri G Rao3 shared
- Tony Velkov3 shared
Most similar at Colorado State University
Same institution · by research overlap
- Mercedes Gonzalez-Juarrero$6,903,366
- Michael A. Lyons$3,329,683
- Mary Jackson$25,157,631
Others in their field
Other Rising Stars on “Regimen”
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Jason Dickens · Duke University$12,259,409
- Chris Maxwell · National Institute Of Allergy And Infectious Diseases$12,000,000
- Carolina Porras · Fundacion Inciensa$10,814,023
- Colin Osborne · University Of Texas Med Br Galveston$10,407,745
- Sabrina Paganoni · Massachusetts General Hospital$9,298,517
Research focus
RegimenIn VivoRattusResistancePowder Dose FormIn VitroLungPropertyFormulationInhalationDrynessAnimal ModelDrug KineticsHospitalsAerosolsInfectionAntibioticsBiological AvailabilityAntibiotic ResistanceFutureBactericideBacterial ResistanceAdverse EffectsEfficacy Evaluation
Grant awards (8)
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$1,663,595
R01 · FY2025 · AI
Inhalational therapy with spectinamides within new regimens of TB therapy$788,086
R01 · FY2025 · AI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$623,786
R01 · FY2025 · AI
Inhalational therapy with spectinamides within new regimens of TB therapy$817,405
R01 · FY2024 · AI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$732,598
R01 · FY2024 · AI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$627,834
R01 · FY2024 · AI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$691,193
R01 · FY2023 · AI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$548,207
R01 · FY2023 · AI